May 21, 2018 / 6:11 AM / a month ago

BRIEF-Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis

May 21 (Reuters) -

* GENENTECH'S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS

* GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS

* GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below